Drug · DIN 02225166
SUPREFACT
Yes: authorized and sold in Canada
Authorized, and the company reports that it sells it in Canada.
Status Marketed since June 5, 2020; first marketed December 30, 1996.
- Drug Identification Number (DIN)
- 02225166
- Company (DIN owner)
- Cheplapharm Arzneimittel GmbhGreifswald, Mecklenburg - West Pomerania, Germany
- Schedule
- Prescription
- Dosage form
- Solution
- Route
- Subcutaneous
- Therapeutic class (ATC)
- Buserelin L02AE01
- Class
- Human
- Record last updated
- July 27, 2026
Active ingredients
As listed in the Drug Product Database.
| Ingredient | Strength | Per |
|---|---|---|
| BUSERELIN (BUSERELIN ACETATE) | 1 MG | ML |
Notices of Compliance
Health Canada approvals that name this DIN.
- June 4, 2020: NOC 23725New Drug Submission (NDS) · Change in Product Ownership
- May 4, 2006: NOC 7930New Drug Submission (NDS) · Manufacturer name change
- June 12, 2000: NOC 993New Drug Submission (NDS)
- July 17, 1996: NOC 4252New Drug Submission (NDS)
Other DINs named SUPREFACT
- DIN 02225158 · Cancelled Post Market